Objective: We analyzed the risk factors for pulmonary metastasis from giant cell tumor of bone and aimed to discuss their therapeutic strategy and appropriate follow-up period. Methods: We analyzed 141 patients of giant cell tumor of bone. The variables analyzed included age, gender, primary site, Campanacci grading, surgical treatment on the primary lesion, radiotherapy and local recurrence. Results: Pulmonary metastasis occurred in 12 patients. The risk factors were young age, Campanacci Grade III and local recurrence. Median time from initial surgery to metastasis was 1.3 years (0-3.1 years). Among them, eight patients experienced local recurrence of the primary tumor, and the median time from initial surgery to local recurrence was 0.8 years (0.3-2.9 years). Among seven patients who underwent wide resection, three patients showed local recurrence of the soft tissue. Nine patients underwent metastasectomy for pulmonary metastases. Of three patients who did not undergo metastasectomy, one patient died of uncontrollable metastases, and two patients showed no changes in their metastatic lesions. Conclusions: Although we found a correlation between local recurrence and pulmonary metastasis, we were still unable to prevent local or metastatic recurrence by wide resection. Local recurrence and metastasis have been found within~3 years after initial surgery, and routine image examinations of the primary site and chest after initial surgical treatment should be considered for at least 3 years postoperatively.
Introduction
Although giant cell tumor of bone (GCTB) is recognized as a locally aggressive but benign tumor (1) , it is also known to sometimes cause pulmonary metastasis (2) (3) (4) . Its mechanism of development is considered to be a tumor-directed vascular invasion (5-7) and iatrogenic embolization (2, 3, 8) . However, the precise cause is still considered controversial. Pulmonary metastasis is known for its slow growth (9) , in some circumstances for its spontaneous regression (4, 10, 11) , and different characteristic traits from malignant tumor. Risk factors for pulmonary metastasis of GCTB have been previously reported; however, few reports have analyzed detailed risk factors in a large-scale retrospective study (12, 13) . While there have been reports on therapeutic methods for pulmonary metastasis (2, 4, 12, 13) , there are no reports on their follow-up periods. In this study, we analyzed clinical data for pulmonary metastasis treated at our institution, with an aim to discuss (i) risk factors and (ii) therapeutic strategies and optimal follow-up periods for pulmonary metastasis of GCTB.
Patients and methods
We retrospectively examined 192 patients of GCTB at our institution from 1979 to 2012. The inclusion criteria were as follows: (i) patients who underwent an initial surgical treatment for a primary lesion at our institution, (ii) patients with over 3 consecutive years of follow-up and (iii) patients who showed no malignant transformation. Patients who died as a result of GCTB were included, even if the follow-up period was <3 years. Fifty-one patients were excluded, including 35 patients who had experienced initial treatment at other institutions, fifteen patients with <3 years of follow-up period due to relocation or loss of contact and one patient exhibiting malignant transformation. As a result, 141 patients were subjects of our study. Age, gender, site of primary lesion, radiographic grade, treatment method for primary lesion, detection of recurrence and detection of pulmonary metastasis were examined. We adopted the Campanacci grading system for radiographic classification (Fig. 1) .
Time periods for the follow-up observation were defined as follows: time from initial consultation to the final follow-up date, time from initial surgery for primary lesion to the first detection of pulmonary metastasis, time from confirmation of pulmonary metastasis to metastasectomy and time from confirmation of pulmonary metastasis to the final follow-up date. All patients received preoperative chest imaging examinations and postoperative chest imaging examinations obtained every 3-6 months. The modality was radiography until 1992 and computed tomography thereafter (Fig. 2) . For the treatment of pulmonary metastasis, metastasectomy was not immediately performed at initial diagnosis. As spontaneous shrinkage of pulmonary metastasis of GCTB was reported, surgery was only performed when increases of the volume and number of metastatic lesions had been confirmed to consider its feasibility. Pathological diagnoses for primary lesion and pulmonary metastasis were conducted by two or more specialists in musculoskeletal sarcoma, and all patients were described as typical giant cell tumors. Pathological confirmation of pulmonary metastasis was only conducted for patients who underwent metastasectomy. In regard to patients undergoing non-surgical treatment, nodules were diagnosed with image findings as metastasis of GCTB if and only if the chest physician ruled out the possibility of pulmonary metastasis of other malignant tumors or respiratory disorders with available clinical information and findings, blood examinations and image research.
For statistical analyses, we used the Mann-Whitney U test for median difference and Fisher's exact test and chi-square test for ratio difference. We defined statistical significance as P < 0.05. Data were analyzed using IBM SPSS Statistics version 21, R version 3.0.1. This study design was approved by an ethics review board.
In this study, we analyzed the data before the introduction of denosumab, an anti-receptor activator of nuclear factor-kappa B ligands (RANKL) antibody for the treatment of GCTB.
Results
The data of the 141 GCTB patients from this study are summarized in Table 1 . Local recurrence was found in 38 patients (27%). The median time from primary surgery to recurrence was 1.4 years (0.3-19.7 years). The median follow-up period was 9.9 years (2.3-34.9 years).
Pulmonary metastasis was found in 12 patients (8.5%). A detailed summary of these 12 patients is shown in Table 2 . Eight patients exhibited local recurrence of primary tumor and median time from primary surgery to recurrence was 0.8 years (0.3-2.9 years). Among them, three patients underwent wide resection for primary tumor and exhibited soft tissue recurrence. The median time from primary surgery to pulmonary metastasis was 1.3 years (0-3.1 years). All patients developed pulmonary metastasis within~3 years postoperatively (Fig. 3) . Examining the time of emergence for local recurrence and metastasis, five patients developed metastasis either after or in conjunction with recurrence. The median time from recurrence to metastasis was 0.6 years (0-1.6 years). On the other hand, three patients showed recurrence after the emergence of metastasis, and the median time from metastasis to recurrence was 0.6 years (0.2-0.9 years).
We examined patients with or without pulmonary metastasis while considering their age, gender, site of primary lesion, Campanacci grading, local treatment for primary lesion, radiotherapy and local recurrence. We found that risk factors of pulmonary metastasis include age, Campanacci grading and local recurrence ( Table 3 ). The average age of patients with pulmonary metastasis was significantly lower than that of patients without pulmonary metastasis (P = 0.01). In terms of primary tumor sites, 25% (1/4 patients) were located in the proximal fibula and 20% (1/5 patients) in the proximal humerus and distal ulnar, showing a relatively high frequency of occurrence; however, there were no specific primary sites where pulmonary metastasis was statistically significant and likely to occur. We could not detect statistically significant differences in patients with primary tumor sites who were previously reported with high incidence of pulmonary metastasis (knee joint (14) , distal radius (2,10,11), axial bone (13) and spine (15) ) to other sites (Table 4 ). In examining radiographic patterns of bone destruction, we found a significantly higher rate (P = 0.02) of pulmonary metastasis in Campanacci Grade III lesions.
There was no significant difference between surgical treatments for primary tumor and the use of combined radiotherapy. On the contrary, a significant difference was observed between local recurrence of primary tumor and pulmonary metastasis (P = 0.003).
We performed surgical treatment for nine patients with pulmonary metastasis. The median time from pulmonary metastasis to pulmonary metastasectomy was 0.6 years (0.1-2.3 years). Five patients Four patients with multiple metastases were unable to undergo total resection with the exception of their large metastatic lesions. All four patients neither developed new metastatic lesions nor increased their volume in unresected metastases, and regression was observed in some metastatic lesions. The median time from unresected metastasis diagnosis to final follow-up was 6.2 years (2.9-31.9 years).
Three patients did not undergo pulmonary metastasectomy. Among them, two patients revealed no changes in volume and thus have been subjected to ongoing follow-up. Median time from pulmonary metastasis to final follow-up of the two aforementioned patients was 12.1 and 18.9 years, respectively. One patient exhibited multiple pulmonary metastases 4 months after a wide resection of the primary lesion. This case was diagnosed unresectable due to a rapid increase in volume and number of lesions within a short time frame (Fig. 4) . Although the patient underwent chemotherapy, local recurrence was also detected, and the patient was died of disease (DOD) caused by a progression of pulmonary metastasis 2.1 years after its appearance.
There was no difference in characteristics between patients with progression of metastatic lesions (increased volume and number) and patients with stable metastatic lesions ( Table 5) .
Discussion
It has been reported that pulmonary metastasis of GCTB is rare and its rate of incidence is 2-9% (3,4,10,12-14,16-18). The cause of pulmonary metastasis has been reported to originate in its vascular invasive nature (5-7), while invasive operations such as curettage have been suggested to dislodge and deposit the tumor into the blood vessel (2, 3, 8) . The basis for the former report lies in patients who have pulmonary metastasis before undergoing surgical treatment for primary lesions. As for the latter, many patients have been reported to generate pulmonary metastasis after undergoing multiple curettages for primary tumor (2, 17) . At our institution, we had one patient with pulmonary metastasis at initial treatment and seven patients with metastasis after performing wide resection. Thus, we have come to support the former proposition more than the latter. The most commonly reported risk factor for pulmonary metastasis is local recurrence (2, 10, 11, 13, 14, (16) (17) (18) . Other factors reported are site of origin (distal radius (2,10,11), knee joint (14) , axial bone (13) and spine (15)), progression of primary lesion (Enneking Stage III (13, 14, 18) and Campanacci Grade III (19) ) and age (13) .
Only Chan et al. (13) reported a statistically significant difference and cited local recurrence, axial bone-generated, young age and Enneking Stage III as risk factors. In this study, we found no significant difference in sites of origin; however, local recurrence, young age and Campanacci Grade III showed significance in generating pulmonary metastasis. Among them, age and Campanacci Grade are predetermined factors at initial treatment by nature of the disease. In contrast, local recurrence can be managed by enhancing the curability of primary tumor resection. Thus, by electing wide resection of tumor instead of curettage, we expect to prevent local recurrence and decrease the onset rate of pulmonary metastasis. Nevertheless, seven patients developed pulmonary metastases after undergoing wide resection in our study, and metastases appeared within 3 years after initial surgery. Additionally, in patients with local recurrence <3 years after initial surgery, there was no appearance of pulmonary metastasis. It is suggested that there are two causes that generate local recurrence: insufficient curettage and common factors that coincide with pulmonary metastasis. In other words, patients without a predisposition for metastasis should not trigger pulmonary metastasis even when exhibiting local recurrence due to insufficient curettage, and patients with this predisposition may possibly generate local recurrence even if it undergoes wide resection of tumor. It is reported that there are no specific histological findings such as vascular invasion in the histopathological image of GCTB (20, 21) . To this account, it is difficult to find a specific predisposition for metastasis in the histopathological image of GCTB. In recent years, Mosakhani et al. (22) suggested that miR-136 and NFIB detected by miRNA microarray have been related with metastasis. Moreover, Quattrini et al. (23) reported that cooverexpression of NFIB, RANK and RANKL was largely related with pulmonary metastasis by immunohistochemical analysis by tissue microarray. These biomarker analyses may contribute to the possibility in forecasting metastasis and merits further research.
Though the period up to the appearance of metastases is reported to be 1.9-5.0 years (2, 4, (10) (11) (12) (13) (14) 17, 18) , the median time in our study showed a comparatively shorter period of 1.3 years (0-3.1 years). The reason is presumably due to the follow-up method for pulmonary metastasis of GCTB at our institution, which utilizes chest imaging examination in short intervals in correspondence to musculoskeletal tumors with low malignancy. Past literatures cite rare cases that exhibit pulmonary metastasis within a long-term follow-up. Chan et al. (13) and Siebenrock et al. (11) reported a case of pulmonary metastasis that developed 24 years after the initial treatment. However, it is rare to exhibit metastasis in a long-term follow-up. Considering the results from our study, the recommended follow-up period for pulmonary metastasis is at least 3 years after initial surgical treatment. As for the treatment of pulmonary metastasis, Rock et al. (2) recommended proactive surgical treatment such as wedge resection or lobectomy, while Chan et al. (13) proposed a resection only when accompanied by a lesion growing larger or developing a symptom after confirming its histological background by biopsy. Viswanathan et al. (12) and Campanacci et al. (4) recommended resection when it is feasible. The reason not to recommend aggressive pulmonary metastasectomy is due to cases of pulmonary metastasis of GCTB that often exhibit no changes in volume and show self-limited characteristics such as spontaneous regression. In our study, we recognized that residual metastatic lesions in patients with insufficient resection of pulmonary metastases showed a median time of 6.2 years, during which period no enlargement in volume was observed. Moreover, two of three patients undergoing follow-up observation did not exhibit any increase in volume for a median time of 12.1 and 18.9 years after occurrence of metastases, respectively. We performed surgical treatment for these metastatic lesions when we recognized increases in volume and numbers of lesions 2 years after metastasis. Eight of nine patients exhibited no metastasis after pulmonary metastasectomy and one case exhibited no change in volume of metastatic lesion for 17 years after the new pulmonary lesion was found. We consider it unnecessary to perform pulmonary metastasectomy immediately after the diagnosis of metastasis and consider it more appropriate to perform resection only when we recognize an increase in volume and number of metastases. Additionally, after detection of pulmonary metastasis, frequent radiographic examinations prove to be indispensable to confirm that the volume and number of metastatic lesions are stable. Although a biopsy of the metastatic lesion is necessary when the chest physician clinically suspects a disease other than the pulmonary metastasis of GCTB, we consider that observation by imaging examination is adequate. The mortality rate of reported metastatic cases varied widely from 0 to 23% (2-4,10-14,18,19) . In our study, one patient resulted in DOD, and this inoperable case was caused by the drastic increase in volume and number of lesions after diagnosis of pulmonary metastasis. We believe that when only the volume of the metastatic lesion is increased, aggressive pulmonary metastasectomy is appropriate. Above all, when metastatic lesions increase in volume, frequent examinations are necessary after detection of metastasis in order to prevent delays in surgery.
Treatment for GCTB may considerably change with the advent of denosumab. Although the efficacy of denosumab in pulmonary metastasis is currently unknown, its prospects will likely be elucidated with further collection of cases in future studies. In this study, findings on the pulmonary metastases of GCTB prior to the introduction of denosumab were compiled, which may provide beneficial information for future comparative research on the clinical use of denosumab.
Conclusions
In conclusion, the risk factors for pulmonary metastasis of GCTB are as follows: young age, Campanacci Grade III and local recurrence. However, wide resection has not necessarily contributed to controlling pulmonary metastasis. In order to avoid drastic increase of metastasis in volume and number, early detection and optimal follow-up observation periods are essential. We recommend the detection of pulmonary metastasis by chest imaging examination for 3 years from initial surgical treatment. After the detection of pulmonary metastasis, radiographic examinations should be obtained frequently until confirming that metastatic lesions are stable. As for treatment of pulmonary metastasis, immediate resection after detection is unnecessary. When the metastatic lesion is confirmed to be increasing in volume and number, a resection of the growth site is recommended.
